Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
19
BAYRY Quote, Financials, Valuation and Earnings
Last price:
$4.86
Seasonality move
:
-1.69%
Day range:
$4.79 - $5.14
52-week range:
$4.79 - $9.79
Dividend yield:
0.6%
P/E ratio:
--
P/S ratio:
0.38x
P/B ratio:
0.56x
Volume:
834.2K
Avg. volume:
2.2M
1-year change:
-45.53%
Market cap:
$19.1B
Revenue:
$51.6B
EPS (TTM):
-$0.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BAYRY
Bayer AG
|
$11B | $0.17 | -5.74% | -27.67% | -- |
|
AFMD
Affimed NV
|
$1.5M | -$1.06 | -50.03% | -42.4% | $18.90 |
|
BNTX
BioNTech SE
|
$561.1M | -$1.75 | -24.68% | -74.38% | $137.54 |
|
CVAC
CureVac NV
|
$150.6M | $1.54 | -66% | -69.73% | $7.38 |
|
IFRX
InflaRx NV
|
$84.1K | -$0.27 | 5602.11% | -2.23% | $8.04 |
|
IMTX
Immatics NV
|
$17.4M | -$0.28 | -5.77% | -3.64% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BAYRY
Bayer AG
|
$4.87 | -- | $19.1B | -- | $0.03 | 0.6% | 0.38x |
|
AFMD
Affimed NV
|
$1.24 | $18.90 | $20.3M | -- | $0.00 | 0% | 20.08x |
|
BNTX
BioNTech SE
|
$114.13 | $137.54 | $27.4B | 184.86x | $0.00 | 0% | 8.34x |
|
CVAC
CureVac NV
|
$2.99 | $7.38 | $670.8M | 5.45x | $0.00 | 0% | 1.13x |
|
IFRX
InflaRx NV
|
$2.51 | $8.04 | $147.8M | -- | $0.00 | 0% | 800.79x |
|
IMTX
Immatics NV
|
$7.10 | -- | $863M | -- | $0.00 | 0% | 5.70x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BAYRY
Bayer AG
|
-- | 0.334 | -- | 0.81x |
|
AFMD
Affimed NV
|
31.93% | 0.815 | 16.35% | 1.76x |
|
BNTX
BioNTech SE
|
1.26% | 0.543 | 0.96% | 7.10x |
|
CVAC
CureVac NV
|
-- | 2.309 | -- | 6.10x |
|
IFRX
InflaRx NV
|
-- | 4.286 | -- | 4.34x |
|
IMTX
Immatics NV
|
-- | 1.740 | -- | 3.87x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BAYRY
Bayer AG
|
$5.4B | -$4.2B | -2.23% | -2.79% | -37.17% | $1.6B |
|
AFMD
Affimed NV
|
-- | -$15.7M | -127.62% | -158.94% | -9594.22% | -$13.2M |
|
BNTX
BioNTech SE
|
$1.2B | $11.5M | -2.32% | -2.35% | 13.39% | -$770.2M |
|
CVAC
CureVac NV
|
$519.1M | $404.1M | 21.3% | 21.3% | 75.06% | $381.2M |
|
IFRX
InflaRx NV
|
$216K | -$16.9M | -61.55% | -61.55% | -14084.63% | -$11.2M |
|
IMTX
Immatics NV
|
-- | $565.3K | -16.88% | -16.88% | -4.19% | -$42M |
Bayer AG vs. Competitors
-
Which has Higher Returns BAYRY or AFMD?
Affimed NV has a net margin of -41.96% compared to Bayer AG's net margin of -9767.12%. Bayer AG's return on equity of -2.79% beat Affimed NV's return on equity of -158.94%.
Company Gross Margin Earnings Per Share Invested Capital BAYRYBayer AG48.94% -$1.17 $34.3B AFMDAffimed NV-- -$1.03 $28.2M -
What do Analysts Say About BAYRY or AFMD?
Bayer AG has a consensus price target of --, signalling upside risk potential of 55.85%. On the other hand Affimed NV has an analysts' consensus of $18.90 which suggests that it could grow by 1421.72%. Given that Affimed NV has higher upside potential than Bayer AG, analysts believe Affimed NV is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings BAYRYBayer AG0 0 0 AFMDAffimed NV5 1 0 -
Is BAYRY or AFMD More Risky?
Bayer AG has a beta of 1.041, which suggesting that the stock is 4.07% more volatile than S&P 500. In comparison Affimed NV has a beta of 2.063, suggesting its more volatile than the S&P 500 by 106.315%.
-
Which is a Better Dividend Stock BAYRY or AFMD?
Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.6%. Affimed NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays -80.89% of its earnings as a dividend. Affimed NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BAYRY or AFMD?
Bayer AG quarterly revenues are $11B, which are larger than Affimed NV quarterly revenues of $170.5K. Bayer AG's net income of -$4.6B is lower than Affimed NV's net income of -$16.7M. Notably, Bayer AG's price-to-earnings ratio is -- while Affimed NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.38x versus 20.08x for Affimed NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BAYRYBayer AG0.38x -- $11B -$4.6B AFMDAffimed NV20.08x -- $170.5K -$16.7M
-
Which has Higher Returns BAYRY or BNTX?
BioNTech SE has a net margin of -41.96% compared to Bayer AG's net margin of 15.91%. Bayer AG's return on equity of -2.79% beat BioNTech SE's return on equity of -2.35%.
Company Gross Margin Earnings Per Share Invested Capital BAYRYBayer AG48.94% -$1.17 $34.3B BNTXBioNTech SE85.63% $0.89 $21.6B -
What do Analysts Say About BAYRY or BNTX?
Bayer AG has a consensus price target of --, signalling upside risk potential of 55.85%. On the other hand BioNTech SE has an analysts' consensus of $137.54 which suggests that it could grow by 20.51%. Given that Bayer AG has higher upside potential than BioNTech SE, analysts believe Bayer AG is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings BAYRYBayer AG0 0 0 BNTXBioNTech SE11 5 0 -
Is BAYRY or BNTX More Risky?
Bayer AG has a beta of 1.041, which suggesting that the stock is 4.07% more volatile than S&P 500. In comparison BioNTech SE has a beta of 0.217, suggesting its less volatile than the S&P 500 by 78.349%.
-
Which is a Better Dividend Stock BAYRY or BNTX?
Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.6%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays -80.89% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BAYRY or BNTX?
Bayer AG quarterly revenues are $11B, which are larger than BioNTech SE quarterly revenues of $1.4B. Bayer AG's net income of -$4.6B is lower than BioNTech SE's net income of $217.9M. Notably, Bayer AG's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 184.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.38x versus 8.34x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BAYRYBayer AG0.38x -- $11B -$4.6B BNTXBioNTech SE8.34x 184.86x $1.4B $217.9M
-
Which has Higher Returns BAYRY or CVAC?
CureVac NV has a net margin of -41.96% compared to Bayer AG's net margin of 68.44%. Bayer AG's return on equity of -2.79% beat CureVac NV's return on equity of 21.3%.
Company Gross Margin Earnings Per Share Invested Capital BAYRYBayer AG48.94% -$1.17 $34.3B CVACCureVac NV95.56% $1.65 $809.4M -
What do Analysts Say About BAYRY or CVAC?
Bayer AG has a consensus price target of --, signalling upside risk potential of 55.85%. On the other hand CureVac NV has an analysts' consensus of $7.38 which suggests that it could grow by 144.29%. Given that CureVac NV has higher upside potential than Bayer AG, analysts believe CureVac NV is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings BAYRYBayer AG0 0 0 CVACCureVac NV3 4 0 -
Is BAYRY or CVAC More Risky?
Bayer AG has a beta of 1.041, which suggesting that the stock is 4.07% more volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BAYRY or CVAC?
Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.6%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays -80.89% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BAYRY or CVAC?
Bayer AG quarterly revenues are $11B, which are larger than CureVac NV quarterly revenues of $543.2M. Bayer AG's net income of -$4.6B is lower than CureVac NV's net income of $371.8M. Notably, Bayer AG's price-to-earnings ratio is -- while CureVac NV's PE ratio is 5.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.38x versus 1.13x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BAYRYBayer AG0.38x -- $11B -$4.6B CVACCureVac NV1.13x 5.45x $543.2M $371.8M
-
Which has Higher Returns BAYRY or IFRX?
InflaRx NV has a net margin of -41.96% compared to Bayer AG's net margin of -14092.9%. Bayer AG's return on equity of -2.79% beat InflaRx NV's return on equity of -61.55%.
Company Gross Margin Earnings Per Share Invested Capital BAYRYBayer AG48.94% -$1.17 $34.3B IFRXInflaRx NV-5376.61% -$0.33 $72.9M -
What do Analysts Say About BAYRY or IFRX?
Bayer AG has a consensus price target of --, signalling upside risk potential of 55.85%. On the other hand InflaRx NV has an analysts' consensus of $8.04 which suggests that it could grow by 220.48%. Given that InflaRx NV has higher upside potential than Bayer AG, analysts believe InflaRx NV is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings BAYRYBayer AG0 0 0 IFRXInflaRx NV3 1 0 -
Is BAYRY or IFRX More Risky?
Bayer AG has a beta of 1.041, which suggesting that the stock is 4.07% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.675, suggesting its more volatile than the S&P 500 by 67.534%.
-
Which is a Better Dividend Stock BAYRY or IFRX?
Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.6%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays -80.89% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BAYRY or IFRX?
Bayer AG quarterly revenues are $11B, which are larger than InflaRx NV quarterly revenues of $136.2K. Bayer AG's net income of -$4.6B is lower than InflaRx NV's net income of -$19.2M. Notably, Bayer AG's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.38x versus 800.79x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BAYRYBayer AG0.38x -- $11B -$4.6B IFRXInflaRx NV800.79x -- $136.2K -$19.2M
-
Which has Higher Returns BAYRY or IMTX?
Immatics NV has a net margin of -41.96% compared to Bayer AG's net margin of -16.95%. Bayer AG's return on equity of -2.79% beat Immatics NV's return on equity of -16.88%.
Company Gross Margin Earnings Per Share Invested Capital BAYRYBayer AG48.94% -$1.17 $34.3B IMTXImmatics NV-- -$0.12 $427.2M -
What do Analysts Say About BAYRY or IMTX?
Bayer AG has a consensus price target of --, signalling upside risk potential of 55.85%. On the other hand Immatics NV has an analysts' consensus of -- which suggests that it could grow by 135.92%. Given that Immatics NV has higher upside potential than Bayer AG, analysts believe Immatics NV is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings BAYRYBayer AG0 0 0 IMTXImmatics NV6 0 0 -
Is BAYRY or IMTX More Risky?
Bayer AG has a beta of 1.041, which suggesting that the stock is 4.07% more volatile than S&P 500. In comparison Immatics NV has a beta of 0.743, suggesting its less volatile than the S&P 500 by 25.688%.
-
Which is a Better Dividend Stock BAYRY or IMTX?
Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.6%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays -80.89% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BAYRY or IMTX?
Bayer AG quarterly revenues are $11B, which are larger than Immatics NV quarterly revenues of $55.6M. Bayer AG's net income of -$4.6B is lower than Immatics NV's net income of -$9.4M. Notably, Bayer AG's price-to-earnings ratio is -- while Immatics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.38x versus 5.70x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BAYRYBayer AG0.38x -- $11B -$4.6B IMTXImmatics NV5.70x -- $55.6M -$9.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 2.02% over the past day.
